A randomized trial of icatibant in ace-inhibitor-induced angioedema

New England Journal of Medicine

Volumn 372, Issue 5, 2015, Pages 418-425

  Baş, Murat ^a   Greve, Jens ^c   Stelter, Klaus ^b   Havel, Miriam ^b   Strassen, Ulrich ^a   Rotter, Nicole ^c   Veit, Johannes ^c   Schossow, Beate ^a   Hapfelmeier, Alexander ^a   Kehl, Victoria ^a   Kojda, Georg ^d   Hoffmann, Thomas K ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLEMASTINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; ICATIBANT; PREDNISOLONE; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HUMAN; INJECTION SITE PAIN; MALE; MULTICENTER STUDY; OFF LABEL DRUG USE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; RESPIRATORY TRACT DISEASE; SIDE EFFECT; UPPER RESPIRATORY TRACT; ANALOGS AND DERIVATIVES; ANGIOEDEMA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

AGED; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONISTS; CLEMASTINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PREDNISOLONE; TIME FACTORS;

EID: 84921837310     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1312524     Document Type: Article

References (21)

1. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012; 172: 1582-9.
2. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008; 51: 1624-30.
3. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17: 103-11.
4. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitorinduced angioedema: incidence, prevention and management. Drug Saf 1998; 18: 171-88.
5. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260: 967-70.
6. Bas M, Kojda G, Bier H, Hoffmann TK. ACE inhibitor-induced angioedema in the head and neck region: a matter of time?HNO 2004; 52: 886-90. (In German.)
7. Holm JP, Ovesen T. Increasing rate of angiotensin-converting enzyme inhibitorrelated upper airway angio-oedema. Dan Med J 2012; 59: A4449.
8. Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA Jr. Multicenter study of patients with angiotensinconverting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 2008; 100: 327-32.
9. Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 2001; 46: 1239-43.
10. Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010; 56: 278-82.
11. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-41.
12. Manders K, van Deuren M, Hoedemaekers C, Simon A. Bradykinin-receptor antagonist icatibant: possible treatment for ACE inhibitor-related angio-oedema. Neth J Med 2012; 70: 386-7.
13. Gallitelli M, Alzetta M. Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensinconverting enzyme inhibitors. Am J Emerg Med 2012; 30(8): e1-e2.
14. Bas M, Kojda G, Stelter K. Angiotensin- converting enzyme inhibitor induced angioedema: new therapy options. Anaesthesist 2011; 60: 1141-5.
15. Javaud N, Fain O, Bernot B, Adnet F, Lapostolle F. Bradykinin-mediated angioedema secondary to angiotensin converting enzyme: initiate treatment from the prehospital phase. Ann Fr Anesth Reanim 2011; 30: 848-50. (In German.)
16. Schmidt PW, Hirschl MM, Trautinger F. Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant. J Am Acad Dermatol 2010; 63: 913-4.
17. Dasarathy Y, Lanzillo JJ, Fanburg BL. Stimulation of bovine pulmonary artery endothelial cell ACE by dexamethasone: involvement of steroid receptors. Am J Physiol 1992; 263: L645-9.
18. Hubert C, Houot AM, Corvol P, Soubrier F. Structure of the angiotensin Iconverting enzyme gene: two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem 1991; 266: 15377-83.
19. Hoover T, Lippmann M, Grouzmann E, Marceau F, Herscu P. Angiotensin converting enzyme inhibitor induced angiooedema: a review of the pathophysiology and risk factors. Clin Exp Allergy 2010; 40: 50-61.
20. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykininreceptor blockade on the response to angiotensin- converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-92.
21. Nosbaum A, Bouillet L, Floccard B, et al. Management of angiotensin-converting enzyme inhibitor-related angioedema: recommendations from the French National Center for Angioedema. Rev Med Interne 2013; 34: 209-13. (In French.)